Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eslicarbazepine acetate - Bial

Drug Profile

Eslicarbazepine acetate - Bial

Alternative Names: Aptiom; BIA 2-093; ESL; Eslicarbazepine; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix

Latest Information Update: 27 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bial
  • Developer BIAL; Eisai Co Ltd; Sunovion Pharmaceuticals
  • Class Acetates; Amides; Analgesics; Antiepileptic drugs; Antimigraines; Dibenzazepines; Esters; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase II Migraine
  • Discontinued Bipolar disorders; Fibromyalgia; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 20 Sep 2018 Launched for Partial epilepsies (Adjunctive treatment, In adolescents, In children above six years of age) in Canada (PO)
  • 19 Sep 2018 Registered for Partial epilepsies (Adjunctive treatment, In adolescents, In children above six years of age) in Canada (PO)
  • 11 Sep 2018 Bial completes a phase III extension trial for Partial epilepsy (Monotherapy) in Germany, Hungary, Lithuania, Latvia, Portugal, Spain, Sweden, Estonia, Austria, Bulgaria, Slovakia, Finland, Czech Republic, Belgium and Croatia (PO) (NCT02484001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top